- Optimi Health (OPTI) provided an operational update on the progress of its planned year of commercialization
- Since the May 2022 inauguration of its Princeton, B.C. cultivation and processing facility, Optimi Health has secured five domestic psilocybin supply agreements
- The company also signed retail and e-commerce distribution agreements for its Optimi Life line of functional mushroom formulations and supplements
- On August 10th, the company partnered with Canadian psilocybin patient advocate Thomas Hartle to create Blue Serenity, Canada’s first therapeutic psilocybin product for use by approved patients and research entities
- Optimi received an amendment to its Health Canada Controlled Substances Dealers Licence
- Large scale production of MDMA is scheduled to begin in October 2022
- Optimi Health (OPTI) is trading steady at C$0.38 as of 10:15 am ET
Optimi Health (OPTI) provided an operational update on the progress of its planned year of commercialization.
Since Q1 2022, the company has pushed its growth initiative, the year of commercialization, designed to scale all aspects of Optimi Health’s revenue generation in relation to market demand for natural psychedelic and functional mushrooms and synthetic psychedelic substances.
Since the May 2022 inauguration of its Princeton, B.C. cultivation and processing facility, Optimi Health has secured five domestic psilocybin supply agreements with Halucenex Life Sciences, Filament Health, ATMA Journey Centers, SABI Mind, and Bloom Psychedelic Therapy and Research Centre, respectively, as well as one international psilocybin supply agreement with Promises Innovative Recovery Center.
The company also signed retail and e-commerce distribution agreements for its Optimi Life line of functional mushroom formulations and supplements with Well.ca, Healthy Planet, and Vitasave.
On August 10th, the company partnered with Canadian psilocybin patient advocate Thomas Hartle to create Blue Serenity, Canada’s first therapeutic psilocybin product for use by approved patients and research entities. Blue Serenity, and other Optimi product offerings, will be featured in the company’s upcoming psilocybin product catalogue, to be launched later this month.
Optimi received an amendment to its Health Canada Controlled Substances Dealers Licence, allowing it to manufacture and distribute synthetic psychedelics, with the company’s specific commercial focus to be on MDMA.
Large-scale production of MDMA is scheduled to begin in October 2022. This will be the only publicly listed company in the psychedelics sector growing natural psilocybin and producing MDMA for clinical research.
FDA approval for psychedelic therapy is expected within 24 months, and a meeting between Canadian Health Minister Carolyn Bennet and members of the Oregon Psilocybin Advisory Board in August, showed encouraging signs for the business that the regulatory landscape in psychedelics is poised for rapid advancement.
Optimi CEO, Bill Ciprick, said that as policymakers increasingly align around psychedelic therapy and a robust commercial sector developing to meet the challenge of delivering better health outcomes with these substances, Optimi is building a global distribution pipeline and is positioned to be the leader in psychedelic drug supply.
“With hundreds of active clinical trials, we are keeping a keen eye on jurisdictions that are loosening supply regulations and are in active discussions with Health Canada on how to further supply Canadians with homegrown medicine.”
Optimi Health (OPTI) is a Vancouver-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances and functional mushrooms that focus on the health and wellness markets.
Optimi Health (OPTI) is trading steady at C$0.38 as of 10:15 am ET.
